Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Rating of “Buy” from Analysts
Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) has earned a consensus recommendation of “Buy” from the nine research firms that are currently covering the firm, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year […]
More Stories
Trump Says US Has ‘Total Control’ of Hormuz
By Tom Ozimek President Donald Trump said the United States has “total control” over the Strait of Hormuz, while Energy...
US Annual Inflation Rate Stabilizes in July, Slowing to 3.4 Percent
By Andrew Moran Stabilizing energy prices have helped cool off inflation pressures for the second straight month, new government data...
State Department Launches Birth Tourism Prevention Task Force
By Troy Myers The Department of State on Wednesday announced the existence of a task force that has already revoked...
Todd Blanche Sworn In as Attorney General
By Kimberly Hayek Todd Blanche, President Donald Trump’s former personal lawyer, was sworn in Monday as U.S. attorney general and...
16,000 Arrests Made as Part of Operation to Make Washington Safe
By Naveen Athrappully More than 16,000 individuals have been arrested in Washington since the launch of the Make D.C. Safe...
Commercial Chapter 11 Bankruptcy Filings Decrease Annually
By Naveen Athrappully There were 666 commercial Chapter 11 bankruptcy filings made in the United States in July, a 27...